Trusted Second Opinion Partner - Cromwell Hospital

Second Opinion Press

Not exactly, but it can be a helpful addition. Your doctor can advise if Trucheck™ Intelli is a suitable option alongside your usual cancer screenings.

Yes, Trucheck™ Intelli requires a prescription from your doctor. They will guide you on whether it is the right choice for you.

You can request the test through your healthcare provider or we can help connect you with one to discuss it directly.

We can inform your healthcare provider about Trucheck™ Intelli or connect you with our clinical partners to discuss it further.

No, in this case, you should seek immediate medical advice.

Trucheck™ Intelli is helpful for individuals who have no symptoms but are at higher cancer risk due to factors like family history or age. Talk to your doctor to find out if Trucheck™ Intelli is suitable for you.

Trucheck™ Intelli screens for over 70 types of solid Tumour.

Trucheck™ Intelli is effective when taken annually, so we recommend having the test once a year.

Trublood™ uses an advanced technique called immunocytochemistry (ICC) staining to detect Circulating Tumour Cells(CTCs) in your blood. These are cancer cells that may have broken away from the main tumour and entered your bloodstream, potentially helping cancer spread. Trublood™ not only detects the presence of these cells but also identifies different types of cancers by looking at the specific molecular or protein markers. This helps provide valuable insights into your cancer's characteristics and possible progression.

Unlike standard CTC tests that only count the cells, Trublood™ captures, expands, and thoroughly examines the CTCs to identify distinct variations within the cancer, offering a detailed understanding of its characteristics.

Trublood™ detects cancers called carcinomas, which are the types that start in the lining of organs and body surfaces, like the skin, lungs, and colon. However, it doesn't detect blood cancers like leukaemia or lymphoma.

Yes, Trublood™ can often differentiate between cancers originating in glandular cells (like adenocarcinoma) and those in the skin or lung linings (like squamous cell carcinoma).

Trublood™ can detect common cancers like adenocarcinoma, squamous cell carcinoma, and hormone-related (neuroendocrine) tumour, but it might miss some rare types.

Trublood™ identifies the type of epithelial cancer but does not provide information on the tumours grade or aggressiveness.

Trublood™ is designed for detecting carcinoma in patients with cancer symptoms or signs, not for ongoing monitoring by counting CTCs.

The Trublood™ validation study does not include cancers that haven't spread but research indicates that CTCs may be detectable in some cases.

Yes, Trublood™ has been tested in both early-stage and advanced cancers, with an overall accuracy of 94.6%.

Trublood™ isn't a general screening test. It is designed to detect cancer in patients who already have specific symptoms or signs related to a particular organ-related cancer.

Trublood™ is validated for cases with a specific organ suspicion, not for non-specific symptoms like weight loss without a particular organ focus.

A blood sample is taken from a vein, like routine blood tests, but with specific storage and transport requirements.

It is transported in temperature-controlled packaging.

Consult with your doctor for further evaluations.

Trublood™ is a highly specific test, but a biopsy may still be recommended based on your doctor's advice.

You can repeat the test in a month and consult with your doctor.

Yes, doctors use Trublood™ test for detection of organ-specific cancer cases, especially if a biopsy is challenging.

No, Trublood™ test is validated for use only in adults, 18 years and older.

Trublood™ is a non-invasive blood test that can detect the presence of cancer and its type without requiring a tissue biopsy.

Trublood™ tests cannot detect certain cancer types, like blood cancers or some rare carcinomas.

Your doctor may consider Trublood™ test results but will factor in other test results as well.

No, Trublood™ test is not designed to detect blood cancers.

Exacta™ is a detailed test that analyses your genetic profile through DNA and RNA sequencing, looking at the drug pathways, drug toxicity, etc. It looks at how different drugs might work for you, then recommends personalised drug combinations that are most likely to be effective. Your oncologist will use these results to help decide the best treatment plan for you.

Cancer can grow and change quickly, which makes it harder to treat. Starting treatment right away can help stop the cancer from becoming resistant to the medications, reducing the need for more tests later.

The recommendations will only include FDA-approved medications, either for cancer or other conditions. Experimental or unapproved drugs won't be included in the treatment plan.

Yes, liquid biopsy allows frequent monitoring of the cancer's status and response to treatment. It can detect signs of recurrence or resistance and help your doctor adjust your treatment plan to improve the quality of life and survival.

Chemoscale™ tests live cancer cells to find out which drugs or combinations are likely to work best for you. This way, it avoids the costly 'trial and error' method, helping you and your doctor choose the most effective treatments based on real results.

Chemo-Scale™ is helpful for all patients with solid tumours, especially those who are starting chemotherapy for the first time or dealing with cancer that has come back.

Not all chemotherapy drugs work the same for everyone. Chemoscale™ shows which treatments are likely to be effective before starting, thus saving time and resources.

While most molecular tests focus on targeted therapies, Chemoscale™ specifically analyses how a patient's cancer cells respond to chemotherapy drugs, allowing for accurate treatment recommendations.

Chemo-Scale™ is suitable for most cancer patients for whom chemotherapy is a treatment option.

Results are available within 8-10 working days after the sample is received.

The molecular profile of cancer cells changes quickly, providing an advantage that helps them survive and grow. Cancertrack™ monitors these molecular changes in real-time, identifying the signs of recurrence, resistance to treatment, or new weaknesses. This information helps the doctors adjust the treatments promptly.

Cancertrack™ is best indicated at key milestones in cancer treatment and especially during treatment follow-up when imaging shows that the tumour has disappeared, to monitor for recurrence.

While Cancertrack™ provides detailed results, but individual differences in biological functions can sometimes affect the regularities in the outcome. However, this is usually balanced out over a period by sequential evaluation.